In a SEC filing dated Sunday, Incyte, which is both incorporated and headquartered in Delaware, indicated the payment represents roughly five years of disputed royalty payments linked to the drug Jakafi. Quinn Emanuel Urquhart & Sullivan and Paul Hastings represented Wilmington, Delaware-based Incyte.

Click Here To Read The Full Article